We are live on ! Find out more
CARM

Carisma Therapeutics
CARM

Delisted

CARM was delisted on the 10th of October, 2025.

Back to rankings

47 hedge funds and large institutions have $80.2M invested in Carisma Therapeutics in 2018 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more call options, than puts

Call options by funds: $1.52M | Put options by funds: $844K

2% more funds holding

Funds holding: 46 → 47 (+1)

7% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 14

3% more capital invested

Capital invested by funds: $78.2M → $80.2M (+$2.02M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.2% less ownership

Funds ownership: 2.62% → 2.42% (-0.2%)

17% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 12

Holders
47
Holders Change
+1
Holders Change %
+2.17%
% of All Funds
1.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
15
Increased
10
Reduced
12
Closed
14
Calls
$1.52M
Puts
$844K
Net Calls
+$679K
Net Calls Change
+$332K

Top Buyers

Rank Fund Capital Flow
1
NC
Nexthera Capital
New York
+$2.29M
2
Millennium Management
Millennium Management
New York
+$1.62M
3
SSA
Schonfeld Strategic Advisors
New York
+$1.52M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$886K
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$351K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$5.12M
2
SFM
Sphera Funds Management
Israel
-$3.4M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.8M
4
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.38M
5
AWS
AJ Wealth Strategies
New York
-$400K
Name Holding Trade Value Shares
Change 		Change in
Stake
Brown Advisory
26
Brown Advisory
Maryland
$45K -$14.1K -361 -26%
FT
27
Fiduciary Trust
Massachusetts
$43K – – –
VF
28
Virtu Financial
New York
$39K -$39.7K -1,019 -53%
Invesco
29
Invesco
Georgia
$39K -$1.05K -27 -3%
Citadel Advisors
30
Citadel Advisors
Florida
$38K -$54.7K -1,403 -61%
Deutsche Bank
31
Deutsche Bank
Germany
$30K -$49.6K -1,274 -65%
Renaissance Technologies
32
Renaissance Technologies
New York
$30K -$31.2K -801 -53%
Squarepoint
33
Squarepoint
New York
$29K +$26.2K +672 New
Creative Planning
34
Creative Planning
Kansas
$27K +$24.2K +620 New
Royal Bank of Canada
35
Royal Bank of Canada
Ontario, Canada
$12K +$9.82K +252 +1,008%
Wells Fargo
36
Wells Fargo
California
$10K +$9.43K +242 New
CHP
37
Cable Hill Partners
Oregon
$10K +$9.74K +250 New
HFM
38
Hartford Financial Management
Connecticut
$9K – – –
UBS Group
39
UBS Group
Switzerland
$9K +$8.57K +220 New
Morgan Stanley
40
Morgan Stanley
New York
$8K +$3.9K +100 +106%
AG
41
Advisor Group
Arizona
$4K +$1.64K +42 +72%
APA
42
American Portfolios Advisors
New York
$2.15K – – –
Citigroup
43
Citigroup
New York
$1K – – –
RFA
44
Reilly Financial Advisors
California
$1K – – –
CG
45
Cutler Group
California
$1K +$390 +10 +43%
TWA
46
TCI Wealth Advisors
Arizona
$1K +$1.17K +30 New
BBA
47
Baker Bros. Advisors
New York
– -$5.12M -131,221 Closed
Point72 Asset Management
48
Point72 Asset Management
Connecticut
– -$1.8M -46,250 Closed
AWS
49
AJ Wealth Strategies
New York
– -$400K -10,251 Closed
MCM
50
Moore Capital Management
New York
– -$195K -5,000 Closed
1
2
3

CARM Hedge Fund Activity: Q3 2018 in Review

47 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Carisma Therapeutics (CARM) for Q3 2018, worth a combined $80.2M — up 2.6% from $78.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CARM positions and 14 closed out — a net gain of 1 holder — while 10 added to existing stakes and 12 trimmed.

The largest buyer was Nexthera Capital, opening a new position worth an estimated $2.29M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $5.12M sold.

  • 47 institutional investors held Carisma Therapeutics (CARM) as of Q3 2018, up from 46 in Q2 2018.
  • Funds reported $80.2M of Carisma Therapeutics stock for Q3 2018, up 2.6% quarter-over-quarter.
  • 15 funds opened new Carisma Therapeutics positions in Q3 2018 and 14 closed out, a net change of +1 holder.
  • The largest Carisma Therapeutics buyer in Q3 2018 was Nexthera Capital, an estimated $2.29M added.
  • The largest Carisma Therapeutics seller in Q3 2018 was Baker Bros. Advisors, an estimated $5.12M sold.

Based on aggregated 13F filings for Q3 2018.